Board elects new CEO to molecular diagnostics company SIRS-Lab GmbH

10-Aug-2009 - Germany

SIRS-Lab GmbH has elected Barbara Staehelin as new Chief Executive Officer. Swiss national Barbara Staehelin is a biochemist and holds an MBA from INSEAD (Fontainebleau). She is a life science entrepreneur and has also made a career in the diagnostics industry. Until 2006, she was a member of the Global Executive Committee of Roche Diagnostics.

Barbara Staehelin: “The SIRS-Lab team is an impressive group, and I believe the SIRS-Lab technology has the potential to unlock this challenging diagnostic field by industry partnerships and with its own product pipeline.”

Nicolas Fulpius and Katrin Uschmann, Board members, comment: “We are very pleased to have recruited Mrs. Staehelin. She has unmatched experience and competences to lead an innovative company like SIRS-Lab to the next level of its development.”

Other news from the department people

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper